The interferon signature in autoimmune diseases : Current Opinion in Rheumatology The
interferon signature in autoimmune diseases : Current Opinion in Rheumatology Log in or …

There is growing evidence that the commensal bacteria in the gastrointestinal tract (the gut
microbiota) influence the development of autoimmunity in rodent models. Since humans …

Objective To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor
antagonist, in a phase IIb, randomized, double‐blind, placebo‐controlled study of adults with …

Abstract Interferome v2. 0 (http://interferome. its. monash. edu. au/interferome/) is an update
of an earlier version of the Interferome DB published in the 2009 NAR database edition …

While a variety of factors act to trigger or initiate autoimmune diseases, the process of
epitope spreading is an important contributor in their development. Epitope spreading is a …

The incidence of autoimmune diseases is increasing worldwide, thus stimulating studies on
their etiopathogenesis, derived from a complex interaction between genetic and …

Autophagy is a protective and life-sustaining process in which cytoplasmic components are
packaged into double-membrane vesicles and targeted to lysosomes for degradation. This …

Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease
affecting multiple organ systems that runs an unpredictable course and may present with a …

Objective To investigate long‐term safety and tolerability of anifrolumab, a human
monoclonal antibody to the type I interferon (IFN) receptor subunit 1, in patients with …

Objectives The interferon (IFN) signature (IS) in patients with systemic lupus erythematosus
(SLE) includes over 100 genes induced by type I IFN pathway activation. We developed a …